References
- Pitts PJ, Louet HL, Moride Y, et al. 21st century pharmacovigilance: efforts, roles, and responsibilities. Lancet Oncol. 2016;17(11):e486–92.
- Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology. Chichester (UK): John Wiley & Sons; 2012.
- Waning B, Montagne M, McCloskey WW. Pharmacoepidemiology: principles and practice. New York: McGraw-Hill; 2001.
- Couig MP, Merkatz RB. MedWatch: the new medical products reporting program. Am J Nurs. 1993;93(8):65–68.
- An update to the FDA Adverse Event Reporting System (FAERS) public dashboard [Internet]. [cited 2019 Jun 2]. Available from: https://www.fda.gov/media/122827/download
- FDA Adverse Events Reporting System (FAERS) public dashboard | sheet-Qlik Sense [Internet]. [cited 2019 Feb 25]. Available from: https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis
- Introductory guide for MedDRA - MedDRAintroguide_version14_0_March2011.pdf [Internet]. [cited 2018 May 8]. Available from: http://www.who.int/medical_devices/innovation/MedDRAintroguide_version14_0_March2011.pdf
- Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health. 2008;98(8):1366–1371.
- Medicine I of. adverse drug event reporting: the roles of consumers and health-care professionals: workshop summary [Internet]. 2007 [cited 2017 Apr 14]. Available from: https://www.nap.edu/catalog/11897/adverse-drug-event-reporting-the-roles-of-consumers-and-health
- Boyko EJ. Observational research — opportunities and limitations. J Diabetes Complications. 2013;27(6):642–648.
- Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn’s disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech. 2000;50(3):229–235.
- Research C for DE and. Drug Safety and Availability - FDA Drug Safety Communication: drug labels for the Tumor Necrosis Factor-alpha (TNFα) blockers now include warnings about infection with Legionella and Listeria bacteria [Internet]. [cited 2017 May 5]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm270849.htm
- Home - ClinicalTrials.gov [Internet]. [cited 2019 Mar 3]. Available from: https://clinicaltrials.gov/
- MODULE 1 – adverse events: frequency and severity - WHO Vaccine Safety Basics [Internet]. [cited 2019 Jun 2]. Available from: https://vaccine-safety-training.org/frequency-and-severity.html
- Study to assess the safety and efficacy of etanercept in patients treated over the long-term in real-world clinical practice, using data collected by the british society of rheumatology biologics registry - Full Text View - ClinicalTrials.gov [Internet]. [cited 2017 Mar 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT01646385?term=NCT01646385&rank=1
- Characterize patients with moderately active Rheumatoid Arthritis (RA) - Full Text View - ClinicalTrials.gov [Internet]. [cited 2017 Mar 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT01557322?term=NCT01557322&rank=1
- Hauben M, Zhou X. Quantitative methods in pharmacovigilance. Drug Saf. 2003;26(3):159–186.
- Zhang X, Zhang Y, Ye X, et al. Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry. BMJ Open. 2016;6(11):e010643.
- Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–1104.
- Hansen RA, Gartlehner G, Powell GE, et al. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5(6):729–735.e1.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj. 2009;339:b2700.
- Strangfeld A, Listing J. Bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol. 2006;20(6):1181–1195.
- Getz KA, Stergiopoulos S, Kaitin KI. Evaluating the completeness and accuracy of MedWatch data. Am J Ther. 2014;21(6):442–446.
Appendix References
- Kotze PG, Abou-Rejaile VR, Uiema LA, et al. Adalimumab for maintenance therapy for one year in Crohn’s disease: results of a Latin American single-center observational study. Arq Gastroenterol 2014;51(1):39–45.
- Cozijnsen M, Duif V, Kokke F, et al. Adalimumab therapy in children with Crohn disease previously treated with infliximab. J Pediatr Gastroenterol Nutr 2015;60(2):205–10.
- Bouguen G, Laharie D, Nancey S, et al. Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn’s disease. Inflamm Bowel Dis 2015;21(5):1047–53.
- Navas-López VM, Blasco-Alonso J, Girón-Fernández-Crehuet F, et al. Efficacy and safety of adalimumab in the treatment of Crohn´s disease in children. Rev Espanola Enfermedades Dig Organo Of Soc Espanola Patol Dig 2013;105(10):579–84.
- Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn’s Disease. Am J Gastroenterol 2009;104(12):3042–9.
- Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004–2008). Aliment Pharmacol Ther 2009;29(5):527–34.
- Swoger JM, Loftus EV, Tremaine WJ, et al. Adalimumab for Crohnʼs disease in clinical practice at Mayo clinic: The first 118 patients: Inflamm Bowel Dis 2010;16(11):1912–21.
- Surveillance of Humira Injection in Korean Patients – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01083121?term=NCT01083121&rank=1
- Special Investigation in Patients With Crohn’s Disease (All Patients Investigation) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT01298648?term=NCT01298648&rank=1
- Lindsay JO, Chipperfield R, Giles A, et al. A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn’s disease. Aliment Pharmacol Ther 2013;38(1):52–61.
- Miheller P, Lakatos PL, Horváth G, et al. Efficacy and safety of infliximab induction therapy in Crohn’s Disease in Central Europe – a Hungarian nationwide observational study. BMC Gastroenterol 2009;9:66.
- Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohnʼs disease: Inflamm Bowel Dis 2009;15(6):816–22.
- An Audit of Patients With Crohn’s Disease Treated With Infliximab (P06066) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT00988832?term=NCT00988832&rank=1
- Program Extension of Real Life Dosing of Remicade in Austria for Crohn’s Disease (Study P04052)(COMPLETED) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT00724958?term=NCT00724958&rank=1
- Postmarketing Safety Surveillance European Registry of Crohn’s Disease Patients Treated With Remicade or Standard Therapy (MK-2155–035) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT00705614?term=NCT00705614&rank=1
- Vavricka SR, Schoepfer AM, Bansky G, et al. Efficacy and safety of certolizumab pegol in an unselected crohn’s disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2011;17(7):1530–9.
- Emery P, Gallo G, Boyd H, et al. Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 2014;32(5):653–60.
- Bingham CO, Ince A, Haraoui B, et al. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Curr Med Res Opin 2009;25(5):1131–42.
- Feltelius N, Fored CM, Blomqvist P, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64(2):246–52.
- Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNFα treatment in rheumatoid arthritis patients. Autoimmun Rev 2009;8(3):266–73.
- Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52(11):3403–12.
- Dartel SAA van, Fransen J, Kievit W, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013;72(6):895–900.
- Observational Trial With Enbrel – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT00488475?term=NCT00488475&rank=1
- Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01646385?term=NCT01646385&rank=1
- A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT00195403?term=NCT00195403&rank=1
- Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT00195338?term=NCT00195338&rank=1
- Good EULAR Response In Patients With Early Rheumatoid Arthritis – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT01558089?term=NCT01558089&rank=1
- Characterize Patients With Moderately Active Rheumatoid Arthritis (RA) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT01557322?term=NCT01557322&rank=1
- Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01981473?term=NCT01981473&rank=1
- Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/study/NCT01078571?term=adalimumab+OR+etanercept+OR+infliximab+OR+golimumab+OR+certolizumab&recr=Completed&rslt=With&type=Obsr&rank=2§=X430156
- Post-marketing Observational Study in Subjects With Rheumatoid Arthritis – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT00234884?term=NCT00234884&rank=1
- A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01086033?term=NCT01086033&rank=1
- Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01163916?term=NCT01163916&rank=1
- A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01387789?term=NCT01387789&rank=1
- Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT01282372?term=NCT01282372&rank=1
- Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01078090?term=NCT01078090&rank=1
- Drug Use Investigation for Humira® – All Patient Investigation for Rheumatoid Arthritis – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT01076959?term=NCT01076959&rank=1
- Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069 – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01346501?term=NCT01346501&rank=1
- Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT01783730?term=NCT01783730&rank=1
- Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01083693?term=NCT01083693&rank=1
- EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01078402?term=NCT01078402&rank=1
- Kvalvik AG, Lefsaker L, Dyvik S, et al. Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis. Jt Bone Spine Rev Rhum 2007;74(6):606–11.
- Thorne C, Bensen WG, Choquette D, et al. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. Arthritis Care Res 2014;66(8):1142–51.
- Nam JL, Villeneuve E, Hensor EMA, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 2014;73(1):75–85.
- Westhovens R, van Vollenhoven RF, Boumpas DT, et al. The early clinical course of infliximab treatment in rheumatoid arthritis: results from the REMARK observational study. Clin Exp Rheumatol 2014;32(3):315–23.
- Ducoulombier V, Solau E, Coquerelle P, et al. Long-term results of infliximab therapy in rheumatoid arthritis: Experience acquired by the North-Pas-de-Calais hospital network. Joint Bone Spine 2007;74(1):56–9.
- Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 2009;58(4):492–500.
- A Study to Observe Characteristics of Rheumatoid Arthritis in Patients Using Infliximab (Study P04250) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT00705289?term=NCT00705289&rank=1
- Real Life Dosing of Remicade for Rheumatoid Arthritis in Austria Monitored Over 9 Infusions (Study P03756)(COMPLETED) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT00725621?term=NCT00725621&rank=1
- Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT00727298?term=NCT00727298&rank=1
- An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT00760669?term=NCT00760669&rank=1
- Observation of Treatment With Certolizumab Pegol in Daily Practice – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01069419?term=NCT01069419&rank=1
- Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01288287?term=NCT01288287&rank=1
- A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01313858?term=NCT01313858&rank=1
- Cortés-Hernández J, Egri N, Vilardell-Tarrés M, et al. Etanercept in refractory lupus arthritis: An observational study. Semin Arthritis Rheum 2015;44(6):672–9.
- García-Bosch O, Gisbert JP, Cañas-Ventura A, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2013;7(9):717–22.
- Italian Group for the Study of Inflammatory Bowel Disease, Armuzzi A, Biancone L, et al. Adalimumab in active ulcerative colitis: a ‘real-life’ observational study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2013;45(9):738–43.
- Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33(8):946–53.
- Sjöberg M, Magnuson A, Björk J, et al. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther 2013;38(4):377–87.
- Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007;26(5):747–56.
- Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007;26(3):411–9.
- Monterubbianesi R, Aratari A, Armuzzi A, et al. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy. J Crohns Colitis 2014;8(8):852–8.
- Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012;119(8):1575–81.
- Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatol Oxf Engl 2014;53(12):2223–31.
- Piaserico S, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol 2014;94(3):293–7.
- María Fernández-Torres R, Paradela S, Fonseca E. Long-term efficacy of etanercept for plaque-type psoriasis and estimated cost in daily clinical practice. Value Health J Int Soc Pharmacoeconomics Outcomes Res 2015;18(8):1158–61.
- Kimball AB, Rothman KJ, Kricorian G, et al. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol 2015;72(1):115–22.
- Vender R, Lynde C, Gilbert M, et al. One-year, multicenter, open-label, single-arm study evaluating the safety and effectiveness of etanercept for the treatment of moderate-to-severe plaque psoriasis in a Canadian population. J Cutan Med Surg 2013;17(2):129–38.
- de Vlam K, Boone C, The Prove Study Group A. Treatment adherence, efficacy, and safety of etanercept in patients with active psoriatic arthritis and peripheral involvement in Belgium for 66 months (PROVE study). Clin Exp Rheumatol 2015;33(5):624–31.
- Gottlieb AB, Kircik L, Eisen D, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatol Treat 2006;17(6):343–52.
- Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br J Dermatol 2007;156(5):1010–4.
- Antoniou C, Vergou T, Dessinioti C, et al. Etanercept: effectiveness and safety data of a retrospective study. J Eur Acad Dermatol Venereol 2011;25(9):1113–5.
- Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT00322439?term=NCT00322439&rank=1
- Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT00293709?term=NCT00293709&rank=1
- Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT00293722?term=NCT00293722&rank=1
- Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT00708708?term=NCT00708708&rank=1
- An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT01557283?term=NCT01557283&rank=1
- Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT01084668?term=NCT01084668&rank=1
- Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01169987?term=NCT01169987&rank=1
- Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT01077128?term=NCT01077128&rank=1
- Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01076192?term=NCT01076192&rank=1
- Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT01316224?term=NCT01316224&rank=1
- Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01155570?term=NCT01155570&rank=1
- Shear NH, Hartmann M, Toledo-Bahena M, et al. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice. Br J Dermatol 2014;171(3):631–41.
- Kalb RE, Gurske J. Infliximab for the treatment of psoriasis: Clinical experience at the State University of New York at Buffalo. J Am Acad Dermatol 2005;53(4):616–22.
- Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT00725452?term=NCT00725452&rank=1
- Assessment of Long-Term Infliximab for Psoriasis (P05319) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT00779675?term=NCT00779675&rank=1
- Horneff G, Bock FD, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68(4):519–25.
- Prince FHM, Twilt M, Cate R ten, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68(5):635–41.
- Klotsche J, Niewerth M, Haas J-P, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2016;75(5):855–61.
- Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60(9):2794–804.
- Tarkiainen M, Tynjälä P, Vähäsalo P, et al. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatol Oxf Engl 2015;54(7):1170–6.
- Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance] – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT01145352?term=NCT01145352&rank=1
- Dijkmans B, Emery P, Hakala M, et al. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009;36(6):1256–64.
- Martín-Mola E, Sieper J, Leirisalo-Repo M, et al. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28(2):238–45.
- Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT00544557?term=NCT00544557&rank=1
- An Observational, Retrospective, Multicenter, National Study for the Monitoring of Subjects Who Participated in the LoadET Clinical Trial – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT01793285?term=NCT01793285&rank=1
- Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01079182?term=NCT01079182&rank=1
- Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01474876?term=NCT01474876&rank=1
- Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED) – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT00725543?term=NCT00725543&rank=1
- Talarico R, Bazzichi L, d’Ascanio A, et al. Rate of serious infections in Behçet’s disease patients receiving biologic therapies: a prospective observational study. Clin Rheumatol 2013;32(10):1547–8.
- Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet’s disease: a 24-month follow-up study. Rheumatology 2007;46(7):1161–4.
- Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017];Available from: https://clinicaltrials.gov/ct2/show/NCT00938015?term=NCT00938015&rank=1
- Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice – Full Text View – ClinicalTrials.gov [Internet]. [cited 6 March 2017 ];Available from: https://clinicaltrials.gov/ct2/show/NCT01111240?term=NCT01111240&rank=1